During the study, participants will receive the medication to observe how the skin cancer reacts. Researchers will examine blood and tumor samples to look for biomarkers, which are biological signs that can indicate how a person might respond to a treatment. They will also study how myeloid suppressor cells, which are specific immune cells that can prevent the body from attacking cancer, move into the tumor area. This information helps in understanding the biological changes that happen within the cancer cells during therapy.

The purpose of this study is to evaluate how well the combination of these two medications works when injected directly into the tumor in patients with locally advanced skin cancer who have previously tried other treatments. The study will look at whether the tumors shrink or stop growing after receiving this treatment. During the study, patients will receive injections of both medications into their tumors over a treatment period. The doctors will monitor the tumors to see how they respond to the treatment and will take tissue samples from the tumor before treatment starts and later to check the response.

Patients participating in this study must have at least one tumor that can be injected and measured. The study requires patients to be generally well enough to carry out daily activities with some limitations. Blood tests will be performed to ensure that patients have adequate levels of blood cells and that their liver is functioning properly. Women who could become pregnant must have a negative pregnancy test, and male patients with partners who could become pregnant must use two methods of birth control during the study. Patients will need to attend scheduled visits and follow the treatment plan throughout the study.

The medications will be given through intravenous administration (delivered directly into a vein). Nivolumab (also known as OPDIVO) will be given as a solution for infusion at a dose based on body weight, while ipilimumab (also known as YERVOY) will also be administered as an infusion according to body weight. The purpose is to determine if using these medications alone can effectively treat the cancer without the need for surgery or radiation therapy.

The study will monitor patients for up to 24 months after receiving the immunotherapy treatment. During this time, doctors will evaluate how well the treatment works and track the patients’ overall health. The study will look at whether patients can achieve complete removal of cancer using only these medications, without requiring additional treatments like surgery or radiation therapy.

The purpose of the study is to explore whether using Cemiplimab before and after surgery can have anti-tumor effects and lower the chances of the cancer returning. Patients will receive Cemiplimab through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of time, during which patients will be monitored to see how well the treatment works and to check for any side effects. The study aims to understand how the treatment affects the cancer and the patient’s overall health.

Throughout the study, researchers will look at various outcomes, such as how many cancer cells remain after treatment, how long patients stay free from cancer recurrence, and overall survival rates. They will also assess the safety of the treatment and examine changes in the cancer and blood to identify any new markers that could help in future treatments. This research is important for finding better ways to treat high-risk cutaneous squamous cell carcinoma and improve patient outcomes.

The purpose of the study is to evaluate how well these treatments work in patients with this type of skin cancer. The study will observe the patients over a period of time to see how their cancer responds to the treatment. This includes looking at how long the cancer stays under control, how long any positive response lasts, and the overall survival of the patients. The study will also monitor the safety and any side effects of the treatments.

Participants in the study will receive the treatment over a period of time, with regular check-ups to assess their health and the progress of the cancer. The study aims to provide valuable information on the effectiveness of these treatments for patients with advanced squamous cell carcinoma of the skin.

The purpose of the study is to evaluate how well these treatments work in shrinking or eliminating the tumors. Participants in the study will receive either the active treatment or a placebo. The study will last for a period of up to four months, during which the medications will be administered directly into the tumor. The effectiveness of the treatment will be assessed by looking at the overall response of the tumors, which includes both complete disappearance and partial reduction in size.

Throughout the study, the safety of the treatments will also be monitored. This means that any side effects or reactions to the medications will be carefully observed and recorded. The goal is to determine not only how effective the treatments are but also how safe they are for patients with these types of skin cancer. Participants will be required to attend regular visits for treatment and monitoring during the study period.

The purpose of this study is to understand the potential benefits of using Cemiplimab alone compared to using it together with RP1 in patients with CSCC that has spread locally or to other parts of the body. Participants in the study will receive either Cemiplimab by itself or a combination of Cemiplimab and RP1. The study will monitor how the cancer responds to these treatments over time.

Participants will be involved in the study for a period that could last up to 108 weeks, depending on their treatment plan. During this time, they will receive regular treatments and undergo assessments to track the progress of their cancer. The study aims to gather information on how well these treatments work and their safety for patients with advanced CSCC.

The purpose of this study is to compare the effectiveness of the combination of V940 and pembrolizumab with the standard treatment options available for cSCC. Participants in the study will receive either the combination of V940 and pembrolizumab, pembrolizumab alone, or the standard treatment. The study will follow participants over a period of time to observe how well the treatments work in preventing the cancer from returning or spreading. Participants will receive the treatments through injections or infusions, and their health will be monitored regularly by the study team.

This study aims to provide valuable information on whether the new combination treatment can improve outcomes for people with resectable locally advanced cSCC. By participating in this study, researchers hope to find better ways to treat this type of skin cancer and improve the quality of life for those affected by it.

The purpose of the study is to see if Cemiplimab can help prevent the return of cancer in patients who are at high risk of their cancer coming back after initial treatment. Participants in the study will be randomly assigned to receive either Cemiplimab or a placebo. The study will monitor patients over time to see how long they remain free of cancer and to track their overall health and survival. The trial will also look at the safety of Cemiplimab by observing any side effects or health changes that occur during the study.

Throughout the study, patients will have regular check-ups and tests to monitor their health and the status of their cancer. The study aims to provide valuable information on whether Cemiplimab can be an effective additional treatment for patients with high-risk CSCC, potentially improving their chances of staying cancer-free after surgery and radiation therapy.